| Sara Aronica, PA-C | |
|
1000 E Mountain Dr, Wilkes Barre, PA 18711-0027 | |
| (570) 808-7300 | |
| Not Available |
| Full Name | Sara Aronica |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Experience | 3 Years |
| Location | 1000 E Mountain Dr, Wilkes Barre, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235804972 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | MA062751 (Pennsylvania) | Secondary |
| 363A00000X | Physician Assistant | MA062751 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Geisinger Wyoming Valley Medical Center | Wilkes barre, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Geisinger Clinic | 5395657001 | 2866 |
News Archive
The traditional wariness that exists between doctors and hospitals, as well as worries related to anti-trust issues, raise questions about which players have the advantage as the specifics regarding accountable care organizations take shape. Meanwhile, ACOs finally have an advocate.
A team of researchers from Columbia University Medical Center, Weill Cornell Medical College, and Brandeis University has devised a wholly new approach to the treatment of Alzheimer's disease involving the so-called retromer protein complex. Retromer plays a vital role in neurons, steering amyloid precursor protein (APP) away from a region of the cell where APP is cleaved, creating the potentially toxic byproduct amyloid-beta, which is thought to contribute to the development of Alzheimer's.
Women may respond less favorably than men to cardiovascular disease (CV) drug-treatments for enlarged heart, according to NewYork-Presbyterian Hospital/Weill Cornell Medical Center physician-scientists
In a joint study, scientists from The Scripps Research Institute and the Dana-Farber Cancer Institute at Harvard University have uncovered a novel mechanism that dramatically increases insulin sensitivity and reduces the risk of developing type 2 diabetes and cardiovascular disease.
The US Food and Drugs Administration (FDA) has approved Byetta (exenatide) injection as add-on treatment for use with insulin glargine, together with exercise and diet for diabetes type 2 patients who are not responding well enough to glargine alone. Byetta's add-on therapy is for those on glargine with metformin and/or a TZD (thiazolidinedione) or without.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sara Aronica, PA-C 100 N Academy Ave, Danville, PA 17822-9800 Ph: (570) 271-6144 | Sara Aronica, PA-C 1000 E Mountain Dr, Wilkes Barre, PA 18711-0027 Ph: (570) 808-7300 |
News Archive
The traditional wariness that exists between doctors and hospitals, as well as worries related to anti-trust issues, raise questions about which players have the advantage as the specifics regarding accountable care organizations take shape. Meanwhile, ACOs finally have an advocate.
A team of researchers from Columbia University Medical Center, Weill Cornell Medical College, and Brandeis University has devised a wholly new approach to the treatment of Alzheimer's disease involving the so-called retromer protein complex. Retromer plays a vital role in neurons, steering amyloid precursor protein (APP) away from a region of the cell where APP is cleaved, creating the potentially toxic byproduct amyloid-beta, which is thought to contribute to the development of Alzheimer's.
Women may respond less favorably than men to cardiovascular disease (CV) drug-treatments for enlarged heart, according to NewYork-Presbyterian Hospital/Weill Cornell Medical Center physician-scientists
In a joint study, scientists from The Scripps Research Institute and the Dana-Farber Cancer Institute at Harvard University have uncovered a novel mechanism that dramatically increases insulin sensitivity and reduces the risk of developing type 2 diabetes and cardiovascular disease.
The US Food and Drugs Administration (FDA) has approved Byetta (exenatide) injection as add-on treatment for use with insulin glargine, together with exercise and diet for diabetes type 2 patients who are not responding well enough to glargine alone. Byetta's add-on therapy is for those on glargine with metformin and/or a TZD (thiazolidinedione) or without.
› Verified 7 days ago